GAO urges HHS to speed antiviral, prepandemic vaccine plans

Lisa Schnirring
Influenza, General
Pandemic Influenza

Oct 6, 2008 (CIDRAP News) – In a recent progress report to Congress on federal influenza pandemic response planning, the Government Accountability Office (GAO) recognized a host of obstacles but cited two areas that officials could make headway on: finalizing guidance on allocating antivirals and developing guidance on how to prioritize groups to receive prepandemic vaccine in the early stages of a pandemic.

The 72-page report, focusing on the US Department of Health and Human Services' (HHS') pandemic response plans, was published on the GAO's Web site on Sep 30.

Investigators looked at three response components that the GAO and outside experts have said need improvements—pharmaceutical intervention, healthcare surge capacity, and public communications. Though the GAO gave detailed status reports for all three of the areas, it made recommendations only about pharmaceutical interventions.

"We believe that finalizing guidance on the use of pharmaceutical interventions will be crucial for responding to a pandemic outbreak and that the necessary guidance documents should be finalized as soon as possible," the GAO wrote.

In June HHS released draft guidance on the use of antivirals during an influenza pandemic. The agency's goal is to place 75 million treatment courses in the Strategic National Stockpile, and draft guidance proposes that the private sector stockpile 110 million additional treatment courses.

The proposed guidance, developed by an interagency task force, advised that antivirals in government stockpiles be used to treat people who are ill, especially when supplies are scarce, and that antivirals for preventive use be mainly drawn from private stockpiles. The draft document did not attempt to prioritize groups.

In a letter responding to the GAO report, Vincent Ventimiglia, Jr, assistant secretary for legislation at HHS, wrote that the agency is in the process of updating the proposed guidance on antiviral use during a pandemic, on the basis of feedback it received during the public comment period. The comment period was set to end on Jul 3, according to a May 23 Federal Register notice.

In its other recommendation, the GAO advised HHS to release guidance for using and prioritizing prepandemic vaccine designed to protect against a pandemic virus before a vaccine closely matched to the actual pandemic strain is available. Federal officials are already stockpiling a prepandemic vaccine based on the H5N1 virus.

In June HHS released its official guidance on allocating pandemic vaccine, which would be developed after the start of a pandemic and designed to match the circulating strain. HHS officials project that it would take 20 to 23 weeks after the start of a pandemic to start producing the first doses.

As for prepandemic vaccine stockpiles, the GAO report says HHS will oversee the distribution and administration to workers who are needed to keep society functioning until a pandemic vaccine becomes widely available. According to the report, the National Infrastructure Advisory Council has estimated that the critical workforce numbers about 20 million people, and HHS' goal is to stockpile enough to cover that number.

However, HHS has not yet released draft guidance on prioritizing target groups for prepandemic vaccines. HHS officials told GAO investigators that target groups for the prepandemic vaccine would likely resemble those for the pandemic vaccine, but would have more of a critical workforce focus. They also said that a tiered approach like that used for the pandemic vaccine would be needed only if a pandemic occurs before HHS reaches its goal of stockpiling enough for 20 million people.

The GAO said establishing target groups in advance is a key component of pandemic planning and warned that HHS could encounter problems if it doesn't issue graft guidance for prepandemic vaccines in a more timely manner. "This lack of essential information could slow the initial response at the state and local levels and complicate the general public's understanding of the necessity for rationing these interventions," the GAO wrote.

Investigators also said a public comment period after the draft prepandemic vaccine allocation plan is announced is a useful step. "Public participation is an essential component for acceptance of tough decisions that will be required unless and until greater capacity or a universal vaccine can be developed," the report said.

In his response accompanying the GAO report, Ventimiglia wrote that HHS will release its proposed prepandemic vaccine allocation guidance "in the near future."

Bill Hall, an HHS spokesman in Washington, DC, told CIDRAP News that the agency has been working on the draft allocation plan, but that it isn't finished and the agency can't yet say when it will be.

See also:

Sep 30 GAO report

Jun 3 CIDRAP News story "HHS offers pandemic guidance on masks, antivirals"

May 23 Federal Register notice

This week's top reads

  1. 'A national scandal': US excess deaths rose even after pandemic, far outpacing peer countries

    The United States has been in a "protracted health crisis" for decades, the researchers say.

    Mary Van Beusekom
    Grave markers with flowers

  2. Woman dies from brain ameba after flushing nose with RV water

    The woman had amebic meningoencephalitis, a rare, often fatal brain infection caused by the ameba Naegleria fowleri.

    Jim Wappes
    Neti pot in use

  3. Moderna pulls licensing submission for combo flu-COVID vaccine

    Moderna's combination vaccine was intended for adults 50 and older. 

    Stephanie Soucheray

  4. FDA vaccine advisers recommend sticking with JN.1 strain for next COVID vaccines

    The group weighed considerations about newer variants and raised concerns that a strain recommendation might interface with the FDA's new proposed COVID vaccine framework.

    Lisa Schnirring
    woman vaccinated

  5. WHO adds NB.1.8.1 as SARS-CoV-2 variant under monitoring

    Experts say illnesses don't seem more severe and more studies are needed to further assess the risk of antibody escape.

    Lisa Schnirring

  6. WHO warns of rising COVID activity in 3 global regions

    The increase in activity is seen in the Western Pacific, Southeast Asia, and Eastern Mediterranean regions.

    Stephanie Soucheray

  7. Prior COVID vaccination produces immune response against new SARS-CoV-2 strains, study finds

    Neutralizing antibodies tested 90 days after infection were greater in participants who had been vaccinated before their variant infections than in those who had been vaccine-naive.

    Stephanie Soucheray

  8. Iowa, Nebraska announce first measles cases

    Iowa's patient is an unvaccinated adult, and Nebraska's is a vaccinated child who had not traveled outside the state.

    Lisa Schnirring
    measles torso

  9. Viewpoint: Making key COVID vaccine decisions without input, transparency is a public disservice

    Newly announced rules that limit the use of COVID vaccines suggest that federal officials are opposed to open discussion and transparency.

    Vaccine Integrity Project Staff and Advisers
    COVID vaccine vial and syringe

  10. FDA approves formula for fall COVID vaccines

    The agency told vaccine makers that COVID-19 vaccines used in the US starting in fall 2025 should be based on JN.1 lineage strains, preferably the LP.8.1 strain.

    Chris Dall

Our underwriters